Literature DB >> 69691

Parkinson's disease, melanoma, and levodopa.

J Fermaglich, P Delaney.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69691     DOI: 10.1007/BF00312480

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  16 in total

1.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

Authors:  R D Sweet; F H McDowell
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

2.  Further studies on the effects of pituitary growth hormone (STH) on C3H mice bearing a transplanted mammary adenocarcinoma.

Authors:  M C SMITH; T A DAANE; C H LI; M B SHIMKIN; W R LYONS; L L SPARKS; D W FURNAS
Journal:  Cancer Res       Date:  1954-06       Impact factor: 12.701

3.  Multiple primary melanoma.

Authors:  G T PACK; I M SCHARNAGEL; R A HILLYER
Journal:  Cancer       Date:  1952-11       Impact factor: 6.860

4.  Biochemistry of melanin formation.

Authors:  A B LERNER; T B FITZPATRICK
Journal:  Physiol Rev       Date:  1950-01       Impact factor: 37.312

5.  Levodopa and melanoma.

Authors:  A N Lieberman; J L Shupack
Journal:  Neurology       Date:  1974-04       Impact factor: 9.910

6.  Levodopa and malignant melanoma.

Authors:  E Robinson; J Wajsbort; B Hirshowitz
Journal:  Arch Pathol       Date:  1973-03

7.  Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.

Authors:  A J Kastin; A Barbeau
Journal:  Can Med Assoc J       Date:  1972-12-09       Impact factor: 8.262

8.  A retrospective survey of 498 patients with malignant melanoma.

Authors:  R McLeod; N C Davis; J J Herron; R A Caldwell; J H Little; R L Quinn
Journal:  Surg Gynecol Obstet       Date:  1968-01

9.  Stimulation of human-growth-hormone secretion by L-dopa.

Authors:  A E Boyd; H E Lebovitz; J B Pfeiffer
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

10.  Effects of reducing the phenylalanine-tyrosine intake of patients with advanced malignant melanoma.

Authors:  H B Demopoulos
Journal:  Cancer       Date:  1966-05       Impact factor: 6.860

View more
  2 in total

1.  Levodopa and melanoma: three cases and review of literature.

Authors:  F H Rampen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

2.  Malignant melanomas of the nasal cavity after occupational exposure to formaldehyde.

Authors:  M Holmstrom; V J Lund
Journal:  Br J Ind Med       Date:  1991-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.